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Abstract
Cardiovascular and coronary heart diseases involve molecular and tissue level damage 
of blood vessels and heart. Coronary Heart Disease and heart failure are the leading 
cause of mortality worldwide. Stem cell transplantation is emerging as a new treatment 
option. Stem cells are capable to reach and settle down at damaged cardiac tissue. This 
stem cell option also repairs the myocardial infarction area in heart or vascular territories 
and ultimately reduces the infarct-related mortality. Non-invasive cardiovascular imag-
ing monitors the real-time status of cardiovascular remodeling or differentiated stem 
cell autografting. Cardiac magnetic resonance imaging (MRI) and bioluminescence are 
robust non-invasive monitoring techniques to visualize cardiovascular structure changes 
due to myocardial dysfunction or restorative myocardial recovery. The present chapter 
highlights the sources, types, delivery methods of stem cells in cardiovascular treatment, 
advantages and current limitations of stem cell monitoring, scopes of ultra-high field 
cardiac 900 MHz MRI and bioluminescence methods applied in stem cell transplantation, 
to translate stem cell molecular events into clinical success and evaluation of rejuvenation 
rate with future perspectives. In conclusion, right choice of stem cells, pluripotent stem 
cell delivery, transplantation and real-time monitoring of stem cell trafficking enhances 
the stem cell therapeutic efficacy in cardiac engraftment and differentiation.
Keywords: stem cell delivery, transplantation, magnetic resonance imaging, coronary disease, 
cardiac tissue engineering
1. Introduction
Cardiovascular diseases (CVD) and coronary heart disease (CHD) are worldwide leading 
causes of present mortality as high as 32.8% [1]. Last 5-year American Heart Association 
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(AHA) data show high prevalence of heart failure as high as 50% and mortality as high as 
32.8%. Coronary artery bypass grafting (CABG) was routine interventional and surgical treat-
ment to bring low morality of coronary heart disease and now stem cell therapy is a new 
option. Still, major life threat is myocardial necrosis of myocardial tissue that cannot restore 
the original function of myocardium. Currently, stem cell research has opened vista in trans-
plantation therapy, and its feasibility and effectiveness are well proven in animal experiments 
as well as in small-scale clinical trials [2–15].
The present chapter is divided into six sections. Section 1 introduces the evolution of stem cell 
therapy and its mechanism in regeneration and heart restoration. Section 2 introduces dif-
ferent stem cells and their purpose in repair and remodeling myocardium. Section 3 defines 
transplantation. Section 4 describes different modes of stem cell delivery. Section 5 highlights 
the purpose of rapid noninvasive real-time monitoring the myocardial repair and evaluation 
of heart territories. Section 6 reviews different clinical trials, available current nanotechnology 
and tissue engineering tools, and new approaches with future perspectives. A sketch of meta-
bolic regulation during rejuvenation is presented for exploring new thoughts on secretory 
molecules regulating remodeling stem cells to explain regeneration of heart with possibility 
of better regeneration outcome. The chapter is written for interested physicians, surgeons, tis-
sue engineers, scientists, and entrepreneurs.
1.1. Evolution of stem cell therapy: regeneration and healing
History records two types of bone marrow cells (BMC): hematopoietic stem cells [red blood 
cells (RBC), white blood cells (WBC), lymphocytes, macrophages] and bone marrow stroma 
mesenchymal stem cells (osteogenic cells for bone formation, chondrogenic cells for carti-
lage formation, adipogenic cells for fat tissue, and myoblast cells for heart regeneration). 
Stroma mesenchymal cells are sources of stem cells. Now, stem cell treatment is emerging in 
heart regeneration and restoration by using intracoronary, intramyocardial, and epicardial 
injections.
Stem cell transplantation therapy was reported useful first time in recovering myocardial 
viability after myocardial infarction in ischemic heart disease [16]. Later, autologous intracor-
onary delivery of mononuclear bone marrow cells 5–9 days after percutaneous transluminal 
coronary angioplasty [(PTCA); performed within 12 hours of myocardial infarction) was suc-
cessful in 10 patients. Patients showed improved wall motion [2]. These clinical trials showed 
angiogenesis, decreased perfusion defects, and improved ejection fraction by endocardial 
injection of bone marrow cells (BMC) directly in hibernating myocardium useful in heart 
failure patients. Later ‘Myoblast Autologous Grafting in Ischemic Cardiomyopathy MAGIC-
cell-5-combination cytokine clinical trial’ using intracoronary blood stem cells or induced 
pluripotent stem cells along with granulocyte-colony-stimulating factor therapy recorded 
improved angiogenesis and cardiac function [17]. Currently, induced pluripotent stem cells 
bearing specific membrane surface marker proteins are emerging as potential engineered 
cells useful for constructing 3D matrices in cardiac repair.
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1.2. What should be the goal of stem cell therapy?
Stem cells are used as autograft (self-renewing, undifferentiated clonigenic) transplanta-
tion in myocardial repair or regeneration to bring tissue functionality back to normal for 
long-term survival in patients with permanent myocardial damage. Some stem cells are 
used as allograft (multipotent) daughter cells that give rise to multiple progenies [18]. The 
result of this asymmetric replication of stem cells is that after each division of stem cells, 
some progeny enters into the differentiation phase. Bone marrow cells and embryonic stem 
cells have differentiation plasticity and capacity. Goal is achieved by stimulating blood stem 
cells to cardiomyocytes providing a continuous supply of cardiac stem cells by trans-dif-
ferentiation. Other exciting option is ‘therapeutic cloning’ means transplanted stem cells 
reprogram into induced pluripotent stem (iPS) cells at target organ. Still many issues are: (1) 
How many number of optimized stem cells needed when performing cell transplantation 
therapy?; (2) How survival time of transplanted cells can be best monitored?; (3) How do 
transplanted stem cells undergo differentiation into cardiomyocytes, smooth muscle cells, 
or endothelial cells?; (4) Do transplanted stem cells produce electrochemical coupling closer 
to normal myocardial tissue and normal cardiac cells and their functions really recover?; 
(5) What is the mechanism of cell transplantation in the treatment of myocardial perfusion 
and cardiac function after a short enhancement (myocardial cell regeneration or paracrine 
or other)? In nutshell, regeneration and healing of damaged cardiac tissue by myocardial 
repair is critical in survival. For interested readers, myocardial repair refers to the restora-
tion of tissue architecture is shown in Figure 1 and its remodeling of metabolic functions 
after injury is described in Figure 7 in detail. Regeneration is defined as 100% myocardial 
repair and recovery.
Currently, cardiac stem cell therapy researchers are exploring new differentiation and surface 
protein expression markers. Main focus is to design stem cell therapy supports using differ-
ent 3D extracellular matrices, polymeric scaffolds. Most intriguing advances are in innovative 
new methods of safe stem cell delivery with subsequent repair monitoring and follow up of 
stem cell therapy [19]. If incomplete repair, it leaves myocardial scar or fibrosis of collagen or 
necrosis after inflammation. After repair, myocardial recovery involves the proliferation of 
stem cells and interaction with native tissue cells to fill up myocardial mass and extra cellular 
matrix (remodeling) with its improved cellular paracrine function. The improved function 
is monitored by non-invasive MRI and bioluminescent techniques. Moreover, total success 
depends on choice of supporting engineered stem cell delivery method and monitoring the 
extent of repair or regenerating cardiac territories with its visualization by physiochemical 
methods during follow up of post-stem cell therapy benefits.
1.3. Potential mechanisms
Basic mechanism is ‘myocardial revascularization and regeneration’ to combat little or no 
blood supply left to slowly dying heart after myocardial ischemia or infarct or hypoxia. If suf-
ficient oxygen diffusion from endocardium and collateral vessels provide sufficient oxygen 
Stem Cells in Treatment of Coronary Heart Disease and Its Monitoring: Tissue Engineering...
http://dx.doi.org/10.5772/intechopen.70229
113
to preserve progenitor cells, cardiac repair is done by progenitor cell migration from healthy 
adjacent myocardium or from the blood circulation.
During regeneration, in fact, initially myoblasts, hemingioblasts, multipotent BMCs and 
adipocytes transform into cardiac specific progenitor cells. These resident stem cells, circu-
lating hematopoietic cells, progenitor cells and BMCs collectively repair the dying heart by 
establishing revascularization and regeneration of heart as shown in Figure 1. These pro-
genitor cells mainly differentiate into endothelial phenotype and cardiac phenotype to pro-
duce paracrine factors for perivascular incorporation and fusion to develop into myocytes 
and coronary vessels as shown in Figure 2. In this process, it requires specific transcription 
factors.  In nutshell, bone marrow mononuclear stem cells, mesenchymal stem cells, endo-
thelial stem cells, and hematopoietic stem cells undergo local neovascularization, neoangio-
genesis and paracrine function to have positive effect on endogenous cell angiogenesis and 
energy metabolism by secretary molecules to inhibit myocyte apoptosis [20] as shown in 
Figure 2. As a result, heart left ventricle ejection fraction, arteriole, ventricular walls, end-
diastolic and end-systolic ejection volumes, perfusion rate, contractility are improved with 
oxygen sufficiency. Revascularization and differentiation are mainly triggered by cycline 
dependent myocyte membrane surface proteins and remodeling factors as described in detail 
(see Figure 7 in section 6).
1.4. Cardiovascular tissue has progenitor differentiating cells to replenish dead or 
dying cells
Stem cells can be mobilized from bone marrow, fat tissue, or blood, and then cultured to 
produce large numbers of pluripotent stem cells to transplant into the area of heart injury. It 
can be explained by the concept of ‘cardiac chimerism’ that explains the role of putative stem 
cells and progenitor cells present in transplanted heart during regeneration from circulating 
stem cells. For example, human circulating endothelial progenitor cells from bone cells are 
rich in membrane surface proteins such as CD34, CD31, KDR, and c-kit positive myocardial 
Figure 1. Different sources of adult stem cells are shown in heart regeneration in panel A and different conditions of 
myocardial injury are shown for the need of heart regeneration in panel B.
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Figure 2. Panel on top: Different mechanisms are shown for differentiation of stem cells to improve revascularization 
and cardiac regeneration after stem cell therapy. Panel on bottom: Somatic nuclear transfer mechanism is shown for 
differentiated cells. Induced pluripotent cells have potential of cardiac repair and used in treatment.
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differentiation proteins visible in myocardial cell biopsy or cultures [21]. Bone-derived endo-
cardial progenitor cells also do cardiac repair of functional myocardium by declining angio-
genic activity. Bearzi et al. reported chimeric heart containing human myocardium with 
myocytes, coronary arterioles, and capillaries formed in mice injected with human cardiac 
stem cells [22]. It also supported the view of human stem cell therapy of cardiomyopathy 
[22]. The following description introduces readers with stem cell types, sources, stem cell 
engineering, and clinical application in heart repair.
2. Stem cell types and regeneration
Human body has continuously dividing tissues, stable tissues, or permanent tissues. Hema-
topoietic cells in bone marrow continuously divide and readily regenerate. These regener-
ating matured cells are short-lived and continuously replenished by stem cells to maintain 
a constant equilibrium between replicating and dying mature cells, for example, skin and 
Gastrointestinal tract (GIT). Stable tissues with least replicating cells are heart, liver, kidney 
cells, endothelial cells, fibroblasts, and smooth muscle cells. Permanent cells are neuron and 
cardiac muscle cells. They can replicate but cannot terminally differentiate.
2.1. Sources of stem cells
• Embryonic stem cells originate from endoderm of embryo after fertilization. Endoderm 
cells produce 220 kinds of specialized cells during mammalian development by irreversible 
differentiation process [23]. Later, embryonic precursor cells differentiate into adult muscle 
or bone marrow cells, fat stem cells or multipotent cells.
• iPS cells are formed from regular adult cells by a “cocktail” of inducers or transcription 
factors so called “induced” pluripotent stem cells (iPS). These transform into the embryo-
like state, without eggs or embryos. The iPS cells are pluripotent and make any type of 
tissue in human body because iPS cells can resemble genetically and immunologically 
matched with the recipient body. Now, transplantation of these cells into the desired or-
gan offers regenerative therapy of that tissue. However, turning back the biological clock 
of adult cells to an embryonic state is myth or miraculous escape from aging “immortal 
divinity”. Interested readers may read comprehensive review on pluripotent cells [23, 24]. 
Yamanaka, 2007 introduced a combination of genes into adult cells changed their behavior 
as embryonic stem cell, hence called them ‘pluripotent’ stem cells. In fact, four gene trans-
acting factors Oct3/4, Sox2, c-Myc, and Klf4 in adult myocyte cells possibly transformed 
them pluripotent stem cells [24]. Yu et al. 2007 reported the delivery of trans-acting factors 
Oct4, NANOG, Sox2, and LIN28 sufficient to reprogram a human somatic fibroblast cell 
into pluripotent cell bearing same telomerase and surface markers as embryonic cells [25]. 
Now, cellular programming by somatic nuclear transfer or cloning enables iPS cells behav-
ing like embryonic cells [25]. Cloning develops embryo by the injection of new DNA mate-
rial from an adult stem cell to an egg cell whose DNA is removed. This enucleated oocyte 
is the best source of pluripotent stem cells [24] as shown in Figure 2. The said engineered 
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egg  rejuvenates the DNA of adult donor cells means restores telomere length without DNA 
loss during advancing age. This hypothetical idea poses ethical questions. On the other 
side of coin, iPS cells may treat or correct harmful mutations or diseases such as sickle cell 
hemoglobin.
• Cardiac stem cells are composed of four types including: resident stem cells, circulat-
ing hematopoietic cells, circulating progenitor cells, bone marrow cells. These all cells 
have significant role in cardiac regeneration after myocardial infarction. Urbanek et al. 
2005  reported high number of activated stem cells (myocytes, smooth muscle cells, and 
embryonic cells) formed after cell regeneration in acute myocardial infarcts over chronic 
infarcts. Poor cell regeneration caused predisposition to chronic congestive heart failure 
[19]. Answer lies in telomere attrition, leading to decreased telomerase levels in chronic 
infarct and higher telomerase activity in acute infarcts. Telomerase enzyme is a marker 
showing growth potential of myocytes, endothelial cells, and smooth muscle cell lineag-
es. Telomerase protects the DNA at the end of a chromosome during mitosis. Autolo-
gous transplantation raises hope of increasing telomerase activity to correct end stage 
cardiomyopathy.
• Mesenchymal stem cells are nonhematopoietic cells in adult bone marrow and adipose 
tissues. These differentiate or modify in vitro to adopt phenotypic characters of cardiomyo-
cytes and vascular cells by mesenchymal stem cell allogeneic therapy or cardiac repair by 
paracrine function [4].
• Allogeneic stem cells are “off the shelf” mesenchymal stem cell products from bone mar-
row of healthy donor. These are useful in therapy phase I trials as they target the myocar-
dial injury site due to the presence of several stromal cell-derived factor-1 (SDF-1), major 
histocompatibility antigen class 2 molecules, and phenotypes CD145+, CD166+, and CD45− 
protein markers. These cells can differentiate into bone, tendon, fat, and muscle tissues. 
These cells also secrete immunosuppressive cytokines. Moreover, these cells can be ad-
ministered by intravenous route. These stem cells also target and differentiate into cardiac 
myocytes and blood vessels [26].
3. Ideal stem cell transplantation to treat cardiovascular diseases
In stem cell transplantation methods, ideally adult stem cells, embryonic stem cells (ESC), 
or induced pluripotent stem cells (iPSC) are locally fixed at dying myocardial tissue sites. 
However, major challenge is to monitor them timely and confirm the real-time improvement 
in dying or recovering myocardial tissue physiology efficiently to treat the ischemic heart dis-
ease. In other words, capability of MR imaging and monitoring heart metabolism visualize the 
anterior wall in acute myocardial infarction patients to detect improved myocardial perfusion 
and myocardial recovery status. Real-time cell imaging also confirms the efficacy of injected 
bone marrow stem cells (BMC cells) in the recovery of myocardial fragility and viability with-
out any increase in left ventricular ejection fraction (LVEF) [27]. In initial experimental study, 
the success of embryonic stem cell transplantation in rat myocardial ischemia model showed 
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significant recovery as reduced left ventricular expansion and reduced area of  myocardial 
infarction after 3–6 weeks. However, in this recovery process, stem cell transcription factors 
such as Oct3/4, Sox2, Klf4, and c-Myc transformed the embryonic stem cells into induced plu-
ripotent stem cells or iPSCs [28]. These pluripotent cells form regenerative myocardial tissue, 
smooth muscle, or endothelial vascular cells in situ to repair myocardial infarction in heart 
or increased ventricular wall thickness and electrical stability [29]. Recently, different clinical 
centers claim their success differently to transplant pluripotent stem cells in remodeling myo-
cardial muscle or endothelial vascular cells [10, 28–35]. In fact, stem cell treatment centers fol-
low the strategy that pluripotent stem cells may be stable rather than terminally differentiated 
as meta-analysis of randomized controlled clinical trials on stem cell therapy also indicated 
clearly that intracoronary adult bone marrow stem cells improve left ventricular function and 
reduce the risk of recurrent heart failure soon after acute myocardial infarction (AMI) [36]. 
Table 1 shows the major stem cell types commonly used in medical practice using autograft 
or allograft transplantation in myocardial repair. Mainly adult stem cells, embryonic stem 
cells (ESC), or induced pluripotent stem cells (iPSC) are choice.
4. Delivery protocols of stem cell therapy
Each protocol differs in cell retention and regeneration rates depending upon method and 
site of injection, i.e., intracoronary, intramyocardial, transendocardial, or via coronary sinus 
delivery (see Figure 3), time of delivery, inflammatory response. Other factor is timing of 
administration rapid or slow injection rates. The early administration of cells facilitates better 
retention of stem cells or rejuvenating homing signals evidenced in TIME trial [6], while a 
long delay may cause scar formation in the LateTIME trial [7] as highlighted in Tables 2 and 3.
4.1. Intracoronary stem cell therapy
It is done by cell transplantation through transcoronary passage of cells at infarct site along 
with a standard percutaneous transluminal coronary angioplasty (PTCA) procedure or cor-
onary artery bypass grafting (CABG) procedure, with the use of an over-the-wire balloon 
Allogenic origin of stem 
cells
Fate of stem cells Autologous origin of adult 
stem cells
Fate of stem cells
Embryonic stem cells Fetal cardiomyocytes Mesenchymal stem cells Endothelial progenitor cells
Adipose derived stem cells Umblical cord derived cells Endothelial progenitor cells Multipotent adult 
progenitor cells
Resident cardiac stem cells Fetal cardiomyocytes Endothelial progenitor cells Induced pluripotent stem 
cells
Skeletal myoblast cells Bone marrow mononuclear 
CD34+
Table 1. Potential applications of different stem cell types for cardiomyocytes in heart transplantation for myocardial 
repair.
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with central lumen placed at a desired position (see Figure 3). It allows intracoronary cells 
to “home-in” or retention of stem cells by extravasation of BMC to the infarcted area in the 
presence of chemokines and adhesion molecules, SDF-1, and beta-2-integrin factors induced 
by ischemic cell injury [32, 35–37].
Coronary infusion of cells is performed four to six times, with 3-minute sequential balloon 
inflations followed by 3-minute rest periods, to create a “stop flow” situation for maximal 
retention period to come into contact with the microcirculation of the infarct-related artery. 
It maximizes the migration and retention of cells into the infarct and peri-infarct tissues for 
successful transplantation. After transplantation, baseline and post procedure LV angiograms 
are monitored for 24 hours, with cardiac markers checked at every 6 and 12 hours. Injection 
of stem cells into a contralateral artery may increase retention in ischemic area if there are 
well-formed collaterals. Imaging studies further confirm the success of contralateral stem cell 
injections to increase the retention of cells in occluded artery territories. The crucial issues are: 
retention of cells, improved ejection fraction, improved regional wall LV function, microvas-
cular plugging, biodistribution, homing to myocardium, proapoptotic factors in the ischemic 
myocardium, CD34+ cells [35, 38].
Figure 3. Different delivery sites of stem cell injections are shown in panel A. Yag laser with three needles is shown for 
BM Laser Repair procedure to deliver stem cells and rejuvenation molecules in panel B. NOGA Myostar catheter is 
shown for delivery of stem cells in left ventricle in panel C. The evaluation of heart recovery as improved anterolateral 
wall after stem cell therapy by MRI is shown in panel D.
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Study name Published n Days Primary outcome Imaging modality
A. Proven stem cell treatment and evaluation
TOPCARE-AMI 2002 59 4–5.5 -Global LVEF improved 
51–60% in 3 months
-SPECT, echo, MRI
BOOST 2004 60 5–6.3 -Global LVEF improved 
in large infarcts after 6 
months(18 m follow up)
-Cardiac MRI
REPAIR-AMI 2006 187 3–6 -LVEF improved 2.5% in 4 
months
-LV angiography
ASTAMI 2006 97 6–7 -No change in global LVEF 
in 1 year
-SPECT, MRI, echo
LEUVEN-AMI 2006 66 1 -No change in LVEF in 
4 months but regional 
contractility improved & 
infarct size less
-Cardiac MRI, echo
FINCELL 2008 77 3 -LVEF improved 5% in 6 
months but global LVEF 
same after 4 months
-Cardiac MRI, echo
HEBE 2010 200 3–8 -LVEF improved 6% in 6 
months
-Cardiac MRI
B. Other clinical stem cell trials using different stem cell types
Autologous BMNCs CABG + SC 5 1y >5 days old MI Improved perfusion
Autologous BMNCs PTCA + SC 13 3m 5–9 days post MI Better perfusion, wall 
motion, less infarct size
BMNCs+EPCs PTCA + SC 23 4m <3 days post MI Better LVEF, EDV, perfusion, 
% contractile function
BMCs+AC133 CABG + SC 12 3–9 m 0–3 m post MI Better EF, better perfusion
BMNCs EMM + SC 8 3 m severe IHD Improved perfusion, angina, 
contractile function
Autogous BMNCs EMM + SC 14 2 m CHF Improved LVEF, perfusion, 
contractile function
Myoblasts CABG + SC 10 11 m CHF Improved EVEF, contractile 
function
Autologous skeletal 
myoblasts
CABG + SC 12 12 m Old MI + ischemic CAD improved LVDF, regional 
contractility
Autologous skeletal 
myoblasts
IM SC 
injection at 
LVAD site
5 6 m IHD improved LVEF, wall thicker 
at the injection site
Autologous BMCs IC infusion + 
PTCA
30 6 m <5 days post MI Improved LVEF, contractile 
function
Autologous BMSCs IC infusion + 
18 days post 
PTCA
34 3–6 m 10 days post MI Better perfusion, high EDV, 
ESV, wall movement, LVEF
Autologous blood 
SCs + inj G-CSF
IC infusion + 
PTCA
10 6 m >48 hours AMI(old) Higher stent restenosis in 
G-CSF group
Table 2. Randomized control trials showing administration of pluripotent stem cells with primary outcome of improved 
cardiac mass by monitoring improvement in left ventricle ejection function by imaging.
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How success in heart recovery after heart transplantation is assessed? After heart recovery, improve-
ment in cardiac functions is the success key. Important cardiac parameters are improved 
ejection fraction (LVEF), improved contractile function, improved regional wall thick-
ness reduction or improved LV function, Ejection Diastolic and Ejection Systolic Volumes, 
improved perfusion along with decreased adverse perfusion defects,  all these events within 
less than a week as shown in Table 2 and Figure 3 (see panel D). In support, several ran-
domized trials clearly shown that administration of intracoronary autologous bone marrow 
nuclear cells in patients soon after myocardial infarction improved the ejection fraction within 
5 days [8, 39] shown in Table 2 and illustrated in Figure 3 (see panel D). Other randomized 
Clinical trial Administration Engineered tissue construct used Reference
Hirsch et al. 2011
HEBE clinical trial
Intracoronary No change in LVEF in 4 months 
followup
[12]
Roncalli et al. 2011
BONAMI Trial
Intracoronary Pluripotent cells [13]
Traverse et al. 2011 LateTIME 
Trial
Intracoronary Pluripotent cells [7]
Bolli et al. 2011 SCIPIO Trial Intracoronary Pluripotent cells [5]
Makkar et al. 2012 CADUCEUS 
Trial
Intracoronary Pluripotent cells [89]
Zhao et al. 2013 Intracoronary Pluripotent cells [90]
Kurbonov et al. 2013 Intracoronary Engineered stem cells [91]
Forcillo et al. 2013 Via CABG+i.m. Stem cells [92]
Assmann et al. 2013 Via CABG+epicardial Engineered stem cells [93]
Nasseri et al. 2014 i.m Stem cells [94]
Brickwedel et al. 2014 Via CABG Engineered stem cells [95]
Hong et al. 2014 Intracoronary + retrograde 
coronary sinus
Engineered stem cells [96]
Hao et al. 2015 Intracoronary Stem cells [97]
Chang et al. 2015 Intracoronary Stem cells [98]
Gao et al. 2015 Intracoronary Stem cell engineering [99]
Fiarresga et al. 2015 Intracoronary Stem cell engineering [100]
Helseth et al. 2015 Intracoronary Stem cell engineering [101]
Eirin et al. 2015 Intrarenal Pluripotent cells [102]
Lee et al. 2015 Intracoronary Engineered stem cells [103]
Tseliou et al. 2016 Intracoronary Stem cell engineering [104]
Hasan et al. 2016 Intracoronary Stem cell engineering [105]
Xiao et al. 2017 Intracoronary Stem cell engineering [106]
Gao et al. 2017 Intracoronary Pluripotent cells in 3D scaffold [107]
Table 3. A chronology of clinical trials using different stem cell delivery and engineered constructs.
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trials showed clear evidence of improved regional wall LV function [9]. The Repair-AMI trial 
showed a significant decrease in major adverse events [10]. However, several clinical trial 
and pilot studies have failed to demonstrate that bone marrow nuclear cells really improve 
LV function in the setting of acute myocardial infarction because of empirical calibration or 
lack of preclinical results[7, 11–13, 31, 40]. Other critical issue is successful cardiac recovery 
or revived myocardial function rapidly and fast as much as possible. In the previous stud-
ies, most of the autologous bone marrow mononuclear cell implantations were performed 
within week following ST elevation myocardial infarction event. Specific mention here is the 
evidence of most favorable cardiac recovery effect on LV function obtained on the fifth day 
after delivery of stem cells in small cohort of patients in the Repair-AMI trial [10] as shown 
in Figure 3.
In the light of above, it is very important that timing of ‘appropriate stem cell conditioned 
delivery’ in right manner soon after myocardial infarction may have an influence on stem cell 
treatment as highlighted in Figure 3 (see panel C). This timing and delivery issue has debated 
over the stem cell choice, delivery mode of stem cells, and timing of stem cell implantation 
after acute myocardial infarction. Two factors need attention here for successful implantation 
and its action on recovery of myocardium: (1) Release rate of circulating progenitor mono-
nuclear cells from bone marrow within hours of acute myocardial infarction [27, 41, 42]; (2) 
Release of enormous hematopoietic stem cells, endothelial progenitor stem cells, mesenchy-
mal stem cells, and a very small number of embryonic-like pluripotent cells with cardio-
rejuvenating properties [43]. Moreover, other factors are also determinant in the success of 
cardiac rejuvenation such as inadequate cell count, improper processing, and timing of stem 
cell administration.
Important concern in regard to negative findings is timing of stem cell administration. The 
National Heart Lung and Blood Institute sponsored Cardiovascular Cell Therapy Research 
Network reported two prospective clinical trials, TIME [6] and LateTIME [7]. The TIME 
trial was proposed to compare the effects of bone marrow mononuclear source cells deliv-
ered at 3–7 days in patients with predominantly ST elevation myocardial infarction. The 
LateTIME trial proved the hypothesis that delayed delivery of autologous bone marrow cells 
at 2–3 weeks following acute myocardial infarction may improve global LV systolic function. 
LateTIME trial calibrated the cell count and processing issues but did not show any detectable 
improvement in LV function over a period of 2 years [44]. For interested readers, intramyocar-
dial stem cell therapy protocol is described in following section.
4.2. Intramyocardial stem cell therapy protocol
In open heart surgery, direct visualization of the heart is a preferred method as an endocar-
dial approach during supervised intramyocardial injection of stem cells. Using endocardial 
approach for intramyocardial stem cell therapy, a transmyocardial injection of stem cells is 
guided by LV electromechanical mapping with NOGA™ software (Biologics Delivery Systems, 
Diamond Bar, CA) to deliver stem cells in target infarct area [15] as shown in Figure 3. For 
instance, in routine stem cells are injected into nonviable myocardium soon after an observed 
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low cardiac output, by an 8Fr MYOSTAR™ catheter (Biologics Delivery Systems) with nitinol 
tubing and retractable needle set up at a depth of 4.5–6 mm inside cardiac tissue and placed 
at an appropriate angle 45° under fluoroscopy observation as shown in Figure 3. Volumes 
of approximated 0.3 cc of stem cells are injected by manually advancing the needle initially 
at several different space volumes of 1 cm3 in areas of thinned myocardium (<0.5 mm2 by 
MRI). Without motion, still patient is kept under observation. Later, patient is monitored for 
18–24 hours attached with cardiac life support device and recovery, and myocardial viabil-
ity is monitored by continuous real-time LV angiography. First time, Federal Drug Agency 
(FDA) approved the protocol of autologous BMC stem cells as milestone showing salvaged 
hibernating myocardium with improved angiogenesis, 75% decreased perfusion defects, and 
improved 20–29% ejection fraction [17]. Now, improved protocols in clinical trials are in prac-
tice throughout the US and Europe as shown in Tables 2 and clinical trials in recent 5 years 
shown in Table 3.
4.3. Retrograde coronary sinus injection
It is other approach to deliver potentially therapeutic stem cells in coronary sinus. A double 
lumen catheter attached with a larger proximal and a smaller distal balloons is used for deliv-
ery of cells in distal lumen. The stem cells are injected and their transport is confirmed angio-
graphically in the mid- to distal interventricular vein that runs parallel to the left anterior 
descending artery, as shown in Figure 3 panel A.
4.4. Intravenous delivery
This approach depends upon the intravenous access site as shown in Figure 3 panel A. The 
cells get trapped in the lungs, liver, and spleen, so that only a small number may enter in coro-
nary circulation, and myocardial homing is minimal [15]. Myocardial homing depends on the 
expression of adhesion molecules, cytokines, and homing receptors. In following sections, 
growing interest of real-time noninvasive monitoring of pre- and post-cardiac recovery of 
myocardium tissue by advanced 900 MHz MRI methods in preclinical studies and real-time 
stem cell behavior are discussed.  900 MHz MRI facility is available only in laboratory at our 
place in the light of less known facts, limitations and challenges to use this facility.
5. Need of noninvasive in vivo monitoring stem cells in preclinical 
studies
Molecular events by imaging methods offer excellent opportunity to visualize and track stem 
cell behavior in vivo to evaluate their efficacy of cardiac cell recovery or therapy in preclini-
cal studies. Monitoring the settled home-in rejuvenated stem cells functioning well at cardiac 
infarct site is based on the fact that active myocardial metabolite protons and water relax-
ation dynamics is characteristic while 31P MR peaks predict the settled stem cell physiology 
[45]. Ultrasound imaging, positron emission tomography/single photon emission  computed 
Stem Cells in Treatment of Coronary Heart Disease and Its Monitoring: Tissue Engineering...
http://dx.doi.org/10.5772/intechopen.70229
123
tomography (PET/ SPECT), magnetic resonance imaging (MRI), optical imaging, and CT 
imaging are routine molecular imaging techniques. Magnetic resonance of odd-numbered 
protons in cardiac tissue molecules with resonant radiofrequency in high magnetic field gen-
erates the physiological MR cardiac MRI fingerprint as most promising in clinical transforma-
tion to provide the structural-functional information of resettled cardiac mass with superior 
resolution and high sensitivity relatively safer and without radiation [45, 46].
Other major challenges are visualizing myocardial functionality and real-time monitoring the 
status of transplanted stem cell behavior within native tissue as true representative of altered 
or improved visible myocardial territories or metabolic recovery. For this purpose, the smart 
imaging contrast agents or contrast labeling of stem cells offer to visualize the behavior of 
transplanted stem cells in tissue in situ. Different techniques of cell MRI, bioluminescence, che-
miluminescence, myofibril scanning, and DNA end-labeling are routine methods to track myo-
cardial functionality, viability, and fragility [47, 49]. Recently, nanoparticle-labeled stem cells 
have been developed to achieve dephasing susceptibility contrast and monitoring the stem cell 
behavior, physiological changes and molecular events by 900 MHz MR imaging stem cells [50].
5.1. MRI contrast labeling of stem cells: source of contrast in images
Tracking of transplanted stem cells and their behavior in native tissue is done using stem cell 
MRI contrast agents such as gadolinium (Gd) chelating agents (Gd-DTPA) and manganese 
chloride (MnCl
2
) [51–53]. Mostly, these image contrast agents provide longitudinal relaxation 
constant (T1) enhanced positive contrast effects of stem cell originated proton nuclear mag-
netic resonance (NMR) relaxation as shown in Figure 4. Recently, several stem cell specific iron 
oxide paramagnetic/super paramagnetic contrast agents emerged as negative contrast agents. 
Figure 4. The metal (M) is encapsulated in chelator coat (Gd-DTPA in dextran coated SPIO). The water accessibility (τ
m
), 
rotational tumbling time (τ
f
), electron spin state T
1e
 of superparamagnetic metal, chemical exchange rate (τex), and MR frequency (δ) are shown as source of contrast. On right: Distinct longitudinal relaxation T1 constants as graphs at different contrast agent 
concentrations are shown in panel A and respective T1 images are shown in panel B. Reproduced from [52] with permission.
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Iron oxide nanoparticles produce strong transverse relaxation constant/dephased transverse 
relaxation constant (T2/T2*) ratio as negative contrast effect due to dephasing effect [54–56].
5.2. Iron oxide particle stem cell labeling
Super paramagnetic iron oxide nanoparticles (SPION) are family of paramagnetic/ superpara-
magnetic contrast agents. It consists of a ferrite (maghemite or magnetite) core and a polymer 
coating. Depending on the diameter size (including both metal core and polymer coat), the 
nanoparticles can be divided into the SPION (diameter size 60–150 nm), USPION (diameter 
size 10–40 nm), and MION (diameter size 10–30 nm) categories [57]. Ferucarbotran (Resovist®) 
and ferumoxides (Endorem or Feridex®) are MRI enhancement contrast agents approved by 
FDA for clinical diagnosis of liver tumors and metastatic lymph nodes. High concentrations 
of ferromagnetic material can shorten both the T1/T2 constants as well as the effect of T2*, 
resulting in a significant reduction in MR relaxation with higher biological safety of stem cells 
[48, 58–60].
5.3. Positively charged polymer transfection agents
Most of these labeled stem cells do not internalize SPIONs and they need endocytosis poly-
mer boosters. Positively charged polymer transfection agents (TAs) or polycations enhance 
the endocytosis across negatively charged membrane surface. So, they can be coated on the 
surface of magnetic iron oxide particles to boost SPION endocytosis or stem cells nonspe-
cifically uptake these SPION particles through the negatively charged membrane surface. At 
present, composites of SPION and polycation TAs are the most commonly used methods to 
enhance the endocytosis of iron oxide particles [49, 60–62].
• Negative charge on stem cell membrane surface does not permit ferric oxide particles to 
attach them with the stem cells. To accomplish it, iron oxide particle surface modifications 
can enhance cellular endocytosis. In this direction, several surface modification approaches 
of polycation binding, incubation with hematopoietic cells, monoclonal antibody-antigen 
binding, receptor binding, magnetoelectric perforation and others are used in but these are 
still in infancy.
• Positive charged polycation TAs macromolecules such as polylysine or protamine sulfate 
are used in making SPION/TA composites with strong positive/negative interaction or 
cationic polymer material coating [63]. These SPIO/TA composites easily adhere to the 
surface of stem cell membranes and persuade the phagocytosis of iron oxide particles 
without aggregation of SPION particles [51]. Ferumoxides (Feridex) with USPIO (MION-
46 L) and added polycationic TAs have been in use to raise the concentration of intracel-
lular SPION particles [32]. After 4–48-hour incubation with 25 μg Fe/mL TA-(USPION), 
target stem cells demonstrated a significant reduction in T2 signal intensities due to de-
phasing effect [52]. Ferumoxides mixed with protamine sulfate (50:3) μg/ml offers an 
optimized protocol [53].
• Overnight incubation of the human mesenchymal stem cells with hematopoietic CD34+ stem 
cells and specific mammalian cells, increases the iron content in the stem cells 1.47–17.31 pg/
cell [64].
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• Monoclonal antibodies of pancreatic cancer specific antigen (PAP2a) fused with dextran-
modified SPIONs show antigen-antibody reaction to target the iron oxide particles in pan-
creatic cancer cells and promote the receptor-mediated SPIO endocytosis [65].
• Iron oxide particle surfaces can be modified by specific target receptors such as vascular 
cell adhesion molecule-1 and membrane mucin A5. These nanoparticles target specific tis-
sues or organs, but the presence of specific target receptors limits the application of modi-
fied nanoparticles in cell tracking [66, 67].
5.4. Magnetoelectric perforation method
It increases the efficiency of nanoparticle endocytosis. Toxicity testing of mesenchymal stem 
cells, neural stem cells and adipose cells in vitro all indicate safer use of magnetoelectric per-
foration because of less cell incubation time and effective safer SPION contrast agent to target 
cells approved by the FDA [68, 69]. Still, stem cell transplantation biological safety consider-
ations need attention and further research.
5.5. Biosafety of iron oxide particle labeling on stem cells
Cell labeling with iron oxide requires intensive toxicity evaluation tests for every protocol and 
characterization of cell type before translating them in clinical application. Feridex®, Resovist®, 
and Endorem® are FDA-approved agents. These agents in stem cells are cleared by the reticulo-
endothelial system. Peripheral blood mononuclear cells labeled in vitro with Ferumoxide® upon 
administrated these cells through intravenous injection in organs showed localized T2*-weighted 
images and R2* maps of cell migration at the tissue inflammation damage areas [65]. However, 
extensive experiments are needed to verify the bio-safety of paramagnetic SPION contrast agents.
5.6. Sensitivity of in vivo MRI detection of labeled stem cells
The intracellular iron distribution in stem cells influences greatly the MRI detection signal 
from labeled stem cells. Several inherent factors are determinant of image quality such as MRI 
sequence selection, spatial resolution, magnetic field intensity, and surrounding stem cell 
or cardiac tissue heterogeneity to affect the molecule sensitive signal. Known factors are: (1) 
Higher intracellular iron content in cells shortens the relaxation time; (2) The T
2
*-weighted 
image is highly sensitive for iron oxide particle labeling load; (3) Field inhomogeneity and 
surrounding tissues; and (4) MRI sensitivity can reach 3000 times that of T
1
 weighting or 60 
times that of T
2
 weighting due to iron oxide-induced dephasing effect [54]. To nullify the iron-
induced MRI signal sensitivity, specific techniques are chosen. T
2
* sequence or steady-state 
free precession (SSFP) is a choice to detect SPION-labeled cells. However, the T
2
* sequence 
gets artifact by intracellular magnetic field inhomogeneity and interference of the surrounding 
normal tissues at high magnetic field. Fast 3D gradient echo (GE) sequences balance this effect 
of T
2
* sensitivity, spatial resolution within imaging time. At the present time, the best choice is 
gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP), to 
create a positive contrast of SPION free from T
2
* artifacts and high sensitive and specific hyper-
intense signal of cell tracking even for smaller imaging voxel size in the high field MRI [55].
Stem Cells in Clinical Practice and Tissue Engineering126
5.7. Limitations of tracking SPION labeling stem cells
SPION particle cell tracking method for cell labeling has some shortcomings. The MRI sig-
nal in preclinical or clinical studies is usually generated from surrounding tissue areas of 
noninterest cardiopulmonary junction [56]. The paramagnetic material usually accumulates 
in hemorrhagic infarction. So, hemoglobin shows false low signal intensity on T2*-weighted 
image [70]. In case of death and rupture of transplanted cells, targeted SPIO nanoparticles 
can be trapped in surrounding tissue cells or reticuloendothelial cells. Subsequently, SPION 
are redistributed, deposited, or differentiated in extracellular environment to generate false 
positive signal. In author’s opinion, direct iron oxide labeling is only suitable for short-term 
stem cell tracking in vivo or in vitro experiments. Other reason of false negative signal can 
be partial volume effects or low concentrations of cells in one imaging voxel. After every 
cell division, intracellular iron content remains half. So, every cell division evidences gradual 
reduction in cell detection sensitivity. The said fact was reported as MRI nonvisible heart cells 
after 6 weeks post-transplant stem cell administrated to the heart [71]. Despite these limita-
tions and shortcomings, paramagnetic/superparamagnetic iron oxide particles are still highly 
popular in the field of stem cell tracking because of their high sensitivity.
5.8. Reporter gene labeling in stem cells
Reporter gene labeling is other method based on fusion of an MRI reporter gene to a target 
gene in stem cells. In transfection of a target stem cell, genes are incorporated into the cellular 
DNA via transgenic methods. These products of reporter genes are expressed in living stem 
cells and produces reporter gene expression as indirectly MRI visible in vivo. Transgenic gene 
labeling methods are highly valuable in long-term studies of labeled stem cell survival, prolif-
eration, and differentiation in vivo. The MRI reporter gene expression can make two products 
of its expression in stem cells: (1) Intracellular enzymes including β-galactosidase, cytosine 
deaminase, creatinine kinase, tyrosinase, and arginine kinase [72]; (2) Ferritin or transferrin 
receptors [73]. Recently, a MRI reporter gene (a ferritin receptor) has emerged as a choice of 
robust contrast. Excessive expression of ferritin can increase iron uptake. Inside cells, redis-
tribution of intracellular iron enhances transverse relaxation rates and reduces T2 relaxation 
constants. Recently, adenovirus-ferritin reporter gene injection into murine corpus striatum 
generated robust contrast on T2 and T2*-weighted imaging within 5–39 days [74].
Clearly MRI reporter gene imaging is still a choice, but it cannot rule out the potential damage 
to cell proliferation and differentiation. Still open issues are the sources and safety of cells, 
issues relating to gene mutation and sensitivity [75]. Now, MR microimaging technology has 
advanced with available 900 MHz magnetic fields to visualize cardiovascular myofibrillar 
territories up to 30 micrometer resolution using SPION and SPOIT nanoparticle-enhanced 
relaxation susceptibility signal intensities of revived cardiac muscles enough to decipher the 
insight of stem cells as shown in Figure 5. Author developed mice beating heart microimages 
using antibody-coated nanoparticles to visualize cardiac muscle orientation angles as finger-
prints of cardiac revival and rejuvenation [76]. It can be easily noticed that dying heart left 
ventricle wall clearly shows the damage sites with clear muscle mass with altered orientation 
of angle proportional to degree of distortion.
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5.9. Regenerating stem cell in vivo dual optical imaging
Cellular engraftment may be monitored by reporter gene construct (fluc-mrfp-ttk) visualiza-
tion by optical methods such as bioluminescence (BLI), chemiluminescence combined with 
MRI, PET, fusion multimodal imaging (FMI), near infra-red (NIR), and radionuclide meth-
ods [77]. The dual-modality imaging has unique strength to monitor cell delivery, survival 
status, graft morphology, and impact on post-MI remodeling on same platform in less time 
[78]. Recently, application of BLI for tracking transplanted stem cells was reviewed on the 
association of stem cell viability with the therapeutic efficacy of stem cell evaluated in pre-
clinical disease models of vascular disease [79]. Reporter gene technology with BLI provides 
Figure 5. Monitoring cardiac cells by 900 MHz MR microimaging on left panels. Axial image shows details of muscle 
fibers in ventricle wall (shown as arrows). Cardiac muscle fibers are shown on right panels with superparamagnetic iron 
oxide troponin nanoparticles (shown in circle) to indicate angles of muscle fiber orientation on right panels. On top right, 
change in muscle fiber orientation angle is shown before and after infarction (shown as vector directions).
Figure 6. Noninvasive bioluminescence (BLI) monitoring of cardiac differentiation in the experimental model of acute 
myocardial infarction shows BLI images showing decrease in RLuc by CMV promoter and increase in PLuc by cardiac-
specific cTnI promoter in adipose tissue–derived progenitor cells after myocardial implantation. BLI can finely quantify 
cardiac regeneration degree relative to the number of surviving cells under ischemic conditions. See Ref. [80].
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 valuable information about the location and functional status of regenerative cells implanted 
into numerous animal models of disease to define the effectiveness and underlying mecha-
nisms of cardiac cell therapy. The light-emitting capability of BLI illustrates the insights of 
cardiac regeneration [80]. Recently, survival kinetics of induced pluripotent stem cell and 
engraftment of viable cells was monitored by BLI imaging by visualizing the retention of bio-
luminescent agents in adult stem cells as shown in Figure 6 to monitor stem cells [34]. Efforts 
are still continuing for regenerating the heart and using myocardial stem cells in cardiovascu-
lar system in treatment of heart disease or remodeling [81]. Now, new trend of noninvasive 
in vivo MR imaging with spectroscopy is emerging to visualize cardiac muscle metabolites 
[81] and products of gene expression or imaging reporter gene induced inhomogeneity signal 
peaks from regenerating stem cells [82].
6. Future perspectives
Future research may focus on conversion of adult cells into iPS cells, and conversion of these iPS 
cells to relevant cell types to treat individual diseases. In near future, multimodal single platform 
bioluminescent/NIR/FRET optical cum MRI/CT/PET microimaging techniques will emerge to 
track the pluripotent stem cell sensitive superior detection methods by monitoring the distribu-
tion of molecular events in differentiating myocardial progenitor cells in less time. It remains 
to see in coming years if differentiating stem cells remain safe and stem cells are not affected 
by radionuclide, chelators, contrast agents, and electromagnetic radiations used to image these 
cells. To expose these stems cells in different preservative media solutions for storage without 
any effect on their capability to remodeling is also a challenge in tissue engineering art. Before 
transplantation and regrafting, it needs thorough investigation of perfect autograft and met-
abolic compatibility, myocardial contractility to remain viable longer. Larger double blinded 
placebo-controlled clinical trials are needed on trans-aortic or trans-septal approach to reach 
different zones of endocardial necrosis. In cases of intramyocardial or epicardial necrosis, epicar-
dial approach should be compared with endocardial one. Brachial can be an alternate option for 
patients who have peripheral vascular disease with difficult femoral approach. Safer delivery of 
stem cells to the heart opens vista of transplantation of stem cells as tissue-engineered constructs.
Throughout life, every person experiences many injuries and recovers with time spontane-
ously by wound healing, organ recovery, or repair mechanisms without even realizing the 
past injuries in the first place. In this repair and wound healing process, proliferation of exist-
ing stem cells makes an individual capable of repairing or restoring the injured tissue(s). 
In fact, these pluripotent stem cells contain the genetic fingerprint or molecule metabolic 
blueprint as memory of tissue origin how a particular tissue cell was assembled from bio-
molecules and functionalized into physiochemical units of organs constructed to begin with 
from embryonic progenitor cells. If these pluripotent stem cells are maintained artificially in 
physiological cultures, rejuvenation potential of stem cells maintains all properties of bio-
transforming and differentiating into organ cells. This potential offers an excellent oppor-
tunity of clinical applications. In fact, these restorative potentials in stem cells are possible 
due to simultaneous multiple functions of stem cells, such as self-renewal, multipotency, 
and paracrine functions. Of mention, paracrine secretion releases colony-stimulating factors, 
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growth factors,  regulatory energy molecules, and stimulatory cytokines from a number of 
retained stem cells during regenerative processes at tissue sites as shown in recent clinical 
trials in Table 3. These secretary molecules lead to further mobilization of endogenous pro-
genitor cells. We do not understand the complete sequence of underlying mechanisms of stem 
cell during regeneration and cardiac healing, even though everyone experiences the benefits 
of cardiac rejuvenation even without complete knowledge of origin of electrophysiology of 
heart, cardiomyocyte functions, and mechanism of molecular events.
The embryonic stem cells have excellent capacity to differentiate into virtually any type of tis-
sue cells [83]. Presently, investigators and government agencies have intensified the detailed 
search for a similar cell lineage or stem cell rejuvenate database in adults [84]. However, 
many challenges remain to understand how these adult stem cells over-ride the complex 
tasks (failed heart in to beating heart again) to take up residence quickly when placed in just 
the right place to gain control and restore or correct the necessary cardiomyocyte shape to 
assume paracrine functions to perform their multiple plasticity functions in a complex differ-
ent cellular environments (rejuvenation). Other major challenge is perfect retention of these 
cells after implantation via intracoronary, intramyocardial, and retrograde coronary sinus 
approach. In fact, a significant percent of stem cells leaves the heart soon after implantation 
and stem cell administration before they stick at damage site [84]. So, the clinical ramifications 
may be significant but they are limited. One fact is clear that remarkable universal nature of 
stem cells offers the exciting possibility of a universal stem cell transformation capability into 
any tissue cell or organ that can circulate throughout the body and reside wherever needed 
to promote regeneration or repair of local tissue if retention of stem cells is good. These stem 
cells have multiple functions and behave proangiogenic and proparacaine, thereby stem cells 
may consume or produce potentially detrimental substances as indicated in recent clinical tri-
als shown in Figure 7, while stem cells may also survive in nontarget organs [85].
From clinical practice standpoint, the major hurdles to the clinical application and transla-
tional research in regard to adult stem cells are the limited small number of stem cells isolated 
from any adult tissue with successful propagation and harvesting of multipotent adult stem 
cells [86]. Other hurdle is the development of perfect “stem cell cocktails” to optimize the 
proliferation and of adult stem cells and differentiation in timely manner [30]. These hurdles 
indicate the urgent attention on supervised expansion of adult stem cells in cultures uni-
formly keeping stem cell intrinsic properties intact may be the answer to stable retention [87]. 
Although extensive cultures of human adult cells may suddenly change the intrinsic proper-
ties of stem cells in vivo [88], putting them unfit rendering them with no restoring capability 
to repair or reverse the injured or diseased tissue in prospective heart failure patients.
Author offers his opinion that cardiac stem cell therapy in future will have an acceptable wide 
spectrum of preclinical and double blinded placebo-controlled clinical trials on trans-aortic 
or trans-septal approaches solving the issue of epicardial or endocardial necrosis in cardio-
vascular regenerative medicine as shown in Table 3 with emphasis on intracoronary and 
retrograde coronary methods or possibly combined with 3D scaffold biomatrices delivery. 
In  development of engineered and constructed scaffold, intensive investigations will intro-
duce new  rejuvenator secretory molecules in remodeling and metabolic regulation to pro-
vide insight of right choice and optimization for best cardiac repair. Researchers may explore 
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more options of differentiated stem cell remodeling in addition to the engineered constructs, 
 rejuvenative molecules and regenerative metabolic pathways highlighted in clinical trials 
shown in Figure 7. What secretory molecules and metabolic regulatory events are common in 
Figure 7. Different secretory molecules are shown either synthesized or released from damaged myocardium from 
altered cardiomyocyte metabolic pathways (shown in left panel). The process of rejuvenation in stem cells is shown to 
correct the metabolic events (see at top on right) to lead repair, rejuvenation and restoration of cardiomyocyte viability 
with improved functions by remodeling in metabolic steps (shown in bottom at right).
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differentiated stem cell remodeling?. During remodeling, substrates are transported across the 
extracellular membrane into the cytosol and are metabolized in various ways. For oxidation, 
the respective metabolic intermediates [e.g., pyruvate or acylcoenzyme A (CoA)] are trans-
ported across the inner mitochondrial membrane by specific transport systems. Once inside 
the mitochondrion, substrates are oxidized or carboxylated (anaplerosis) and fed into the Krebs 
cycle for the generation of reducing equivalents [reduced nicotinamide adenine dinucleotide 
(NADH)
2
; reduced flavin adenine dinucleotide (FADH)] and GTP. The reducing equivalents 
are used by the electron transport chain to generate a proton gradient, which in turn is used for 
the production of ATP. This principal functionality can be recovered in various ways during 
reverting heart failure (HF), thereby regaining ATP production or  improving cellular function 
in other many ways. Researchers may explore more molecular options of remodeling in addi-
tion to the molecules and regenerative metabolic pathways shown in Figure 7.
Mainly two types of cardiovascular tissue biomaterials synthetic (polymer, ceramic, or met-
als) and biologic (cell-based, extracellular matrix-based, whole tissue) and hybrid bioma-
terials will be available. Advanced therapy medicinal products (ATMP), cardiomyocytes, 
ECM hydrogels and scaffolds, urinary bladder matrix (UBM) scaffolds, glycosaminoglycans 
(GAGs), collagen, fibronectin and laminin matrix, endothelial cells (ECs) and vascular smooth 
muscle cells(VSMCs), poly-tetra fluoro ethylene (PTFE), cardiac patches, cell-seeded matri-
ces, and pericytes seeding with biodegradable tissue engineering-based graft (PLLA/PCL, 
designed to be degraded in 3–5 years) are currently used methods for dynamic seeding with 
total BMCs or selected bone marrow aspirate mononuclear cells (BMMNCs). Electrospinning 
is routine to design scaffolds. For heart regeneration, cell delivery vehicle is implanted 
using smooth muscle cells (SMC), fibroblasts, endothelial progenitor cells, embryonic CD 34 
stem cells, BM cells, tissue-engineered vascular grafts are becoming promised biomaterials. 
Vascular CorMatrix® patch, vascular grafts made of PG/PGA, PCL/PLA polymers offer clini-
cal use [107–109]. The stem cell treatment will have a universal role in reversing the aging 
process, although a natural phenomenon. Naturally with the aging process, there is a continu-
ous decline in stem cell number and their viability or physiochemical cardiac capability with 
time. Due to these facts, aging and heart diseases are interlinked and advancing age promotes 
organ diseases. Therefore, restorative repairing capability of stem cells may provide a renew-
able life, and a “fountain of youth” as evidenced by jelly fish rejuvenation.
7. Conclusion
The in vivo imaging techniques are useful in dynamic monitoring of cardiac stem cell therapy 
following myocardial infarction. Choice of stem cells and mode of delivery are very crucial 
in getting successful stem cell therapy positive outcome. Cardiovascular remodeling evalua-
tion by MRI has merits because it is safe, sensitive, lacks radiation, provides good resolution, 
generates a real-time events’ blueprint or first-hand information of myocardial viability with 
functional information of cardiac territories and their physiochemical changes in cardiac func-
tions during stem cell rejuvenating process and after myocardial repair. Present time, ultra-
high magnetic field CMR possibly has preclinical prospects as in vivo noninvasive molecular 
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imaging or restorative monitoring reporter of rejuvenating stem cell genes to evaluate suc-
cess of transplantation and cardiac repair. On the other side of coin, researchers are continu-
ously developing new real-time physiological cum functional MRSI options to explore new 
stem cell molecular probes and smart MRS imaging sequences with improved MRI sensitive 
specific stem cell differentiation and rejuvenating detection by targeting energy metabolites, 
myocardial viability, and vital physiochemical molecules. Noninvasive monitoring is neces-
sary and bioluminescence or other radionuclide methods may be alarming because the poten-
tial biological damage caused by radionuclide exposed reporter genes and bioluminescence 
induced immune responses is concern in differentiating stem cells. Seriously, all these issues 
need research to minimize artifacts within safe limits. With the help of stem cell imaging and 
monitoring, transplantation of stem cells sooner or later will be optimized for the effective 
long-lasting therapy of myocardial infarction and heart failure on some day.
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